Supply of Products and COVID-19

Supply of Products and COVID-19

{$excerpt:n}

03/2019. Information regarding COVID-19

INMUNOTEK information note on the supply of its products.  

In these extraordinarily difficult times, we want to assure our prescribers and patients that despite the situation of confinement established in Spain, our company continues to work to fulfill its commitments.

We have adapted our production following the sanitary recommendations to avoid contagion from our essential personnel. We continue to regularly manufacture and supply our treatments to our international partners for delivery to patients.

In addition to the key personnel who come to our facilities, many employees at home telecommute to continue to provide our partners, prescribers and patients with the support required of us.

Our lines of communication are still operational. If you have any questions, contact us at info@inmunotek.com.

The INMUNOTEK team

 


La entrada Supply of Products and COVID-19 se publicó primero en Inmunotek.


Source: Inmunotek News

COVID-19: INMUNOTEK invited by ITTN

COVID-19: INMUNOTEK invited by ITTN

{$excerpt:n}

03/2020. ITTN selects MV130 project

The project presented by INMUNOTEK has been selected in the “International Innovative Technology against COVID-19” an event organized by ITTN (International Technology Transfer Network) under the auspices of CAST (China Association for Science and Technology).  

INMUNOTEK has presented its project MV130 based on TIbV (trained immunity-based vaccines), in the “Roadshow & Matchmaking of International Innovative Technology against COVID-19”. MV130 confers antiviral resistance by stimulating innate immunity through stable metabolic and epigenetic changes on innate immune cells.

ITTN has been working since February 2020 with the support of the Science and Technology Exchange Center of CAST, through different partners such as MyBioGate, INNONATION, Global-tech IP and SPICI, to search for innovative projects that allow the fight against epidemic diseases. More than 300 international projects have been evaluated in relation to proposals against COVID-19.

In a first selection made by various expert committees, seven projects were invited to participate in the first online Roadshow  that took place on March 20th 2020. INMUNOTEK opened the session with its presentation (Dr. Laura Conejero). More than 200 Chinese attendees from biopharmaceutical companies, investment, institutions and experts from Zhejiang, Jiangsu, Shanghai, Shenzhen, Zhuhai and other places in China were present.

+info


La entrada COVID-19: INMUNOTEK invited by ITTN se publicó primero en Inmunotek.


Source: Inmunotek News

INMUNOTEK´s research in Allergy Virtual Issue

INMUNOTEK´s research in Allergy Virtual Issue

{$excerpt:n}

03/2020. Virtual Issue includes INMUNOTEK´s research

Virtual Issue is a collection of recently published articles in Allergy selected by the Editor-in-Chief on a topic of high interest that are made available Free Access by the journal. Its aim is to bring these articles to the attention of Allergy readers and to reach a wider audience, such as doctors and other health care professionals, who do not have daily access to academic journals.

The first Virtual Issue is dedicated to leading research on Biologicals and Allergen Immunotherapy (AIT). In this issue the research article carried out in the Department of Biochemistry and Molecular Biology (Faculty of Chemistry, Complutense University of Madrid) under the direction of Prof. Oscar Palomares, and INMUNOTEK has been included:

Alum impairs tolerogenic properties induced by allergoid‐mannan conjugates inhibiting mTOR and metabolic reprogramming in human DCs

Cristina Benito‐Villalvilla, Irene Soria, Mario Pérez‐Diego, Enrique Fernández‐Caldas, José Luis Subiza, Oscar Palomares

Alum is one of the most widely used adjuvants in AIT and in this study the authors provide mechanistic insights on Alum impairing tolerogenic properties elicited by allergoid-mannan conjugates. 


La entrada INMUNOTEK´s research in Allergy Virtual Issue se publicó primero en Inmunotek.


Source: Inmunotek News

Financial Times features INMUNOTEK

Financial Times features INMUNOTEK

{$excerpt:n}

12/2019. INMUNOTEK en Financial Times

The Financial Times features INMUNOTEK as a successful company capable of overcoming economic and political turbulences in a special report on business and innovation in Spain.  

According to the Financial Times (FT), innovation and competitiveness shield Spanish companies from eventual turbulences associated with the economic cycles or political issues. Companies that promote these values ​​are able to access to external markets, have a sustainable growth and create employment.

As an example, FT features INMUNOTEK in the article How Spanish business rides out political turbulence. FT highlights how INMUNOTEK has consistently increased its sales by about 20 percent a year, both in the depths of Spain’s recession in 2009-2012 and in recent years when the economy forged ahead. 

 


La entrada Financial Times features INMUNOTEK se publicó primero en Inmunotek.


Source: Inmunotek News

myTomorrows and Inmunotek to develop Expanded Access Program

myTomorrows and Inmunotek to develop Expanded Access Program

{$excerpt:n}

12/2019. Expanded Access Program

Joint press release from myTomorrows and Inmunotek

myTomorrows and Inmunotek to develop Expanded Access Program

Amsterdam, The Netherlands and Madrid, Spain, 12 December, 2019 – myTomorrows, a Netherlands-based HealthTech company facilitating access to medicines in development and real-world data collection, and Inmunotek – with headquarters in Madrid, Spain – a global player in allergy and immunity-based bacterial vaccines, today announced a collaboration to develop an Expanded Access Program (EAP) for the unlicensed bacterial vaccine Uromune.
Inmunotek is progressing Uromune in a clinical development program as a vaccine for patients with recurrent Urinary Tract Infections (rUTIs). The Expanded Access Program will support the supply of Uromune, when prescribed on a Named Patient basis.
Steve Glass, COO of myTomorrows said, “I am delighted that myTomorrows has found a partner in Inmunotek. With our unique online platform, combined with our global capabilities of supporting expanded access we aim to accelerate access to a medicine in development and serve patients with an unmet medical need.”

Prof. Jose Luis Subiza, MD, CEO of Inmunotek commented, “This collaboration with myTomorrows will allow Inmunotek to expand its geographical presence, to the benefit of those patients who have no other treatment options available. Also, this collaboration will likely contribute to a better understanding of the unmet needs of patients suffering rUTI’s and support further development for concomitant diseases.”

About Expanded Access Programs
An Expanded Access Program (EAP), also known as Managed Access Program, supports in a compliant and controlled way the treatment with a medicine currently not licensed in a patient’s country of residence. Such treatment can be an option for patients who have a high unmet medical need, have exhausted all registered treatment options and cannot participate in a clinical trial.

About myTomorrows
myTomorrows operates as a two-sided platform. It serves the interests of both patients and healthcare professionals, as well as drug development. On one side, the company provides information on all treatment options to patients and physicians when registered treatments have been exhausted. On the other side, myTomorrows is specialized in expanded access regulations and administration and real-world data collection, evolving scientific clinical development. myTomorrows has gained experience in running over 20 EAPs over the past 5 years, in more than 30 countries across 5 continents. For more information, please visit www.mytomorrows.com.

For enquiries about myTomorrows or expanded access, please contact our medical team via medical@mytomorrows.com.

About Inmunotek
Inmunotek is a pharmaceutical company based in Alcalá de Henares – Madrid (Spain) that researches, develops, manufactures and markets products in the field of Allergy and Immunology for the diagnosis and treatment of allergic and other immune-based diseases in human and veterinary medicine. For more information about Inmunotek, please visit www.inmunotek.com.

For Inmunotek, please contact:

Inmunotek
Dr Miguel Casanovas, Medical Director
mcasanovas@inmunotek.com
T: +34 912 908 942

For myTomorrows, please contact:

myTomorrows
Dr. Michel van Harten, CMO
medical@mytomorrows.com
T: +31 88 5253 888

La entrada myTomorrows and Inmunotek to develop Expanded Access Program se publicó primero en Inmunotek.


Source: Inmunotek News

MyTomorrows and INMUNOTEK collaboration

MyTomorrows and INMUNOTEK collaboration

{$excerpt:n}

12/2019. Expanded Access Program

Joint press release from myTomorrows and Inmunotek

myTomorrows and Inmunotek to develop Expanded Access Program

Amsterdam, The Netherlands and Madrid, Spain, 12 December, 2019 – myTomorrows, a Netherlands-based HealthTech company facilitating access to medicines in development and real-world data collection, and Inmunotek – with headquarters in Madrid, Spain – a global player in allergy and immunity-based bacterial vaccines, today announced a collaboration to develop an Expanded Access Program (EAP) for the unlicensed bacterial vaccine Uromune.
Inmunotek is progressing Uromune in a clinical development program as a vaccine for patients with recurrent Urinary Tract Infections (rUTIs). The Expanded Access Program will support the supply of Uromune, when prescribed on a Named Patient basis.
Steve Glass, COO of myTomorrows said, “I am delighted that myTomorrows has found a partner in Inmunotek. With our unique online platform, combined with our global capabilities of supporting expanded access we aim to accelerate access to a medicine in development and serve patients with an unmet medical need.”

Prof. Jose Luis Subiza, MD, CEO of Inmunotek commented, “This collaboration with myTomorrows will allow Inmunotek to expand its geographical presence, to the benefit of those patients who have no other treatment options available. Also, this collaboration will likely contribute to a better understanding of the unmet needs of patients suffering rUTI’s and support further development for concomitant diseases.”

About Expanded Access Programs
An Expanded Access Program (EAP), also known as Managed Access Program, supports in a compliant and controlled way the treatment with a medicine currently not licensed in a patient’s country of residence. Such treatment can be an option for patients who have a high unmet medical need, have exhausted all registered treatment options and cannot participate in a clinical trial.

About myTomorrows
myTomorrows operates as a two-sided platform. It serves the interests of both patients and healthcare professionals, as well as drug development. On one side, the company provides information on all treatment options to patients and physicians when registered treatments have been exhausted. On the other side, myTomorrows is specialized in expanded access regulations and administration and real-world data collection, evolving scientific clinical development. myTomorrows has gained experience in running over 20 EAPs over the past 5 years, in more than 30 countries across 5 continents. For more information, please visit www.mytomorrows.com.

For enquiries about myTomorrows or expanded access, please contact our medical team via medical@mytomorrows.com.

About Inmunotek
Inmunotek is a pharmaceutical company based in Alcalá de Henares – Madrid (Spain) that researches, develops, manufactures and markets products in the field of Allergy and Immunology for the diagnosis and treatment of allergic and other immune-based diseases in human and veterinary medicine. For more information about Inmunotek, please visit www.inmunotek.com.

For Inmunotek, please contact:

Inmunotek
Dr Miguel Casanovas, Medical Director
mcasanovas@inmunotek.com
T: +34 912 908 942

For myTomorrows, please contact:

myTomorrows
Dr. Michel van Harten, CMO
medical@mytomorrows.com
T: +31 88 5253 888

La entrada MyTomorrows and INMUNOTEK collaboration se publicó primero en Inmunotek.


Source: Inmunotek News

National Innovation Award to INMUNOTEK

National Innovation Award to INMUNOTEK

{$excerpt:n}

11/2019. IMMUNOTEK wins the National Innovation Award

INMUNOTEK has been the winner of the 2019 National Innovation and Design Awards of the Spanish Ministry of Science, Innovation and Universities in the Small and Medium-Sized Enterprise category.

These Prices are the most important awards of the Spanish Government seeking to reward those entities that have made innovation an essential factor in the development of their corporate growth.

INMUNOTEK has been awarded with such an important Price as a leading company in research, development, manufacture and marketing products for the diagnosis and treatment of diseases in the field of allergy and immunology, in human and veterinary medicines. The jury highlights its strong economic commitment in constant R&D+i, a technological surveillance system that allows it to capture strategic information of its environment. Also its fast growth as a result of a policy of benefits and provision of funds maintained by the company, which has allowed it to increase its financial independence and strengthen its competitiveness both nationally and internationally.

+info 


La entrada National Innovation Award to INMUNOTEK se publicó primero en Inmunotek.


Source: Inmunotek News

INMUNOTEK awarded as “Best SME of the Year”

INMUNOTEK awarded as “Best SME of the Year”

{$excerpt:n}

11/2019. CEPYME Awards: INMUNOTEK SME of the Year

The Spanish Confederation of Small and Medium Enterprises (CEPYME) has awarded INMUNOTEK as the best company of the year in the sixth edition of its annual awards. 

The awards ceremony has been chaired by the acting Minister of Economy and Business, Nadia Calviño, the president of CEPYME, Gerardo Cuerva, and the CEO of Santander Bank, Rami Aboukhair, as the sponsor of this award. 

The prize SME of the Year is granted to the company that has stood out for its Business Excellence, taking into account the Business Activity, Innovation, Internationalization and Job Creation criteria.

In his thanking speech, the CEO-President of INMUNOTEK, José Luis Subiza, has valued the company’s commitment in knowledge, innovation, material resources but above all, in the competence of the INMUNOTEK team and its ability to face all challenges.

+ info


La entrada INMUNOTEK awarded as “Best SME of the Year” se publicó primero en Inmunotek.


Source: Inmunotek News

BMC publishes a new article on UROMUNE

BMC publishes a new article on UROMUNE

{$excerpt:n}

10/2019. UROMUNE article in BMC Infectious Diseases

The results of a clinical trial conducted with Uromune, a bacterial mucosal vaccine in sublingual spray, developed and manufactured by INMUNOTEK, have been published in BMC Infectious Diseases.

This study analyzes the effectiveness of Uromune for the treatment of uncomplicated recurrent urinary infections, a pathology that has considerable morbidity worldwide and that mainly affects women. The results, obtained in 784 patients, 648 women and 136 men, with documented urine infections by urine culture, indicate a high clinical efficacy of Uromune, confirming previous studies.

The study, carried out in two hospitals in Barcelona (Mataró Hospital and Moisés Broggi Hospital) between 2011 and 2017, concludes that UROMUNE is highly effective in reducing infectious episodes and could be the first choice treatment for the prevention of uncomplicated recurrent urinary tract infections.

Download the article (pdf) 

La entrada BMC publishes a new article on UROMUNE se publicó primero en Inmunotek.


Source: Inmunotek News

Alum impairs the tolerogenic effects of allergoids coupled to mannan

Alum impairs the tolerogenic effects of allergoids coupled to mannan

{$excerpt:n}

10/2019. Aluminum hydroxide and allergoids coupled to mannan

Allergoids coupled to nonoxidized mannan induce tolerogenic effects on dendritic cells. Such effects are inhibited by aluminum hydroxide, a common adjuvant used in allergen vaccines. This is described, as well as the mechanisms involved, in a recent study in Allergy

This research, led by prof. Oscar Palomares (School of Chemistry, Complutense University of Madrid) with the collaboration of INMUNOTEK, highlights the important role of certain metabolic pathways of dendritic cells (DC) activated by allergoid-mannan conjugates for these cells to acquire tolerogenic properties. These pathways are inhibited by aluminum hydroxide, so the ability of DC to induce tolerance to conjugated allergens is also inhibited. 

Download the paper

La entrada Alum impairs the tolerogenic effects of allergoids coupled to mannan se publicó primero en Inmunotek.


Source: Inmunotek News